DexCom Management and Board of Directors

President and CEO
Terrance H. Gregg

Terrance H. Gregg is President and CEO of DexCom, Inc. He is also currently a Special Venture Partner with Galen Partners, a private equity firm specializing in the healthcare industry. In 2002 he retired as President of Medtronic MiniMed, a world leader in diabetes management systems. He became President and Chief Operating Officer of MiniMed, Inc. in 1996 and was instrumental in Medtronic's $3.4 billion acquisition of MiniMed in 2001. He also served in executive positions with Smith and Nephew and Allergan, Inc.

Mr. Gregg served as the 2003-2004 Chair of the Research Foundation Board of the American Diabetes Association.

Mr. Gregg received a Bachelor of Science degree from Colorado State University in 1971. In 2003, Mr. Gregg and his wife were recognized by the American Diabetes Association with an award for Outstanding Service in Diabetes Research Funding.

Senior Vice President of Clinical & Regulatory Affairs and Quality Assurance
Andrew K. Balo

Andy Balo Senior Vice President of Clinical & Regulatory Affairs and Quality Assurance, overseeing all of DexCom's clinical trials, statistical analyses, and regulatory submissions. Mr. Balo is widely regarded as an industry expert in regulatory strategies and sits on several FDA panels including cardiovascular, neurological and gastrointestinal as the industry representative. Mr. Balo has been instrumental in bringing several key medical devices to the market including a neurological cooling device, mechanical and tissue-based heart valves, pacemakers, pacing leads, aortic grafts and electrophysiology mapping devices and has gained approval for over thirty PMA and PMA supplements. Prior to joining DexCom, Mr. Balo held positions as Vice President, Regulatory, and Clinical Affairs for INNERCOOL therapies, Inc. and Endocardial Solutions, Inc.

During the 1990s Mr. Balo held several positions at St. Jude Medical including Vice President, Regulatory, Clinical and Technical Services and Corporate Vice President, Quality, Regulatory and Clinical Affairs and was an officer of the company. Mr. Balo holds a BS in Microbiology and Chemistry from the University of Maryland and has studied at UCLA and Stanford.

Vice President of Quality Assurance
David J. Carner

David Carner joined DexCom as its Vice President of Quality Assurance in August 2010. Mr. Carner has over 20 years experience in the medical device industry with class II and class III devices. He has a rich history as an executive in Quality Assurance and has also held senior leadership positions in Research and Development at large, multi-national organizations such as Abbott Vascular/Guidant, Pacesetter and Intermedics, as well as, smaller venture backed companies such as Broncus Technologies and PhotoThera. At Abbott Vascular, Mr. Carner was Director of Quality Systems responsible for global Quality System integration activities with Guidant Corporation; at Guidant Corporation, Mr. Carner was Director of Quality and part of the management team responsible for the successful launch of the first carotid stent and embolic protection system approved in the United States. Most recently, Mr. Carner was Vice President of Quality Assurance at PhotoThera and then Broncus Technologies where he helped the organizations transition from R&D to commercial operation readiness.

Mr. Carner received a B.S. in Aerospace Engineering at the University of Texas, Arlington.

Vice President of International Business Development
Peter Gerhardsson

Peter Gerhardsson joined DexCom as its Vice President of International Business Development in September 2008. For almost thirty years, Mr. Gerhardsson has worked within the pharmaceutical and medical technology business sector. He has extensive experience with diabetes therapies. Mr. Gerhardsson is responsible for developing DexCom's markets outside of the United States. From 1980 to 2000, Mr. Gerhardsson held various sales and marketing roles for Novo Nordisk, including several senior management positions. From 1991 through 1993, Mr. Gerhardsson led the Far East business for Novo Nordisk, managing its fast-growing presence in China, India, South Korea and the Southeast Asian countries. From 1994 - 2000, he was the Managing Director of the Swedish affiliate. After joining MiniMed in 2000, Mr. Gerhardsson was responsible for operations in the Nordic countries, and later was responsible for all European diabetes business units with Medtronic. In 2005, he rejoined Novo Nordisk as Vice President of Corporate Responsibility, including Socio Economics, Stakeholder relations and Social Responsibility programs.

He has served as a board member of the Association of the Swedish Pharmaceutical Industries.

Mr. Gerhardsson has a Bachelor of Science degree from Lund University Sweden and graduate studies in pharmacology from the Medical School of Linkoping University, Sweden. He holds a diploma in marketing and economics from the Executive Foundation of Lund University, Sweden and an EMBA from Stanford University.

Vice President of Sales
Richard Doubleday

Richard Doubleday joined DexCom as its Vice President of Sales in June 2009, where he oversees DexCom’s sales and sales administration functions. Mr. Doubleday joined DexCom from Johnson & Johnson, where he spent over 21 years at several operating companies, including the past 13 years working in the diabetes space for both LifeScan, Inc. and Animas Corporation. Mr. Doubleday joined Johnson & Johnson in May 1988 as a Retail Sales Representative with Advanced Care Products. He moved to LifeScan in 1996 as a National Account Manager. While at LifeScan, he also served as Area Manager in Consumer Sales, Field Sales Director in Consumer Sales, Field Sales Director in Professional Sales and Marketing Director in the Healthcare Professional Channel. In 2006, Mr. Doubleday moved to Animas Corporation as Director of Brand Marketing, where he was responsible for promotion, positioning and messaging for new and existing products in the Animas portfolio. He then served as Director of Strategic Marketing and Alliances, where he was responsible for developing and managing strategic alliances for Animas as well as helping to craft the long-term portfolio strategy.

Mr. Doubleday has a B.A. from Michigan State University.

Vice President of Marketing
Claudia Graham

Claudia Graham joined DexCom as its Vice President of Marketing in September 2008. Globally recognized as a thought leader in access to diabetes technologies, Claudia is responsible for all product development and commercial marketing activities within DexCom, and is a key liaison with DexCom's co-development partnerships. Prior to joining DexCom, she held multiple positions within Medtronic Diabetes including both Vice President of Global Therapy Access and Vice President of Marketing and Product Development at MiniMed, which was acquired by Medtronic in 2001. Earlier in her career, Claudia was a Director of Marketing for Parke-Davis Pharmaceuticals, a division of Warner Lambert.

She received her PhD from the University of Southern California and her Masters of Public Health from the University of California, Los Angeles. She has served on various national and local boards serving the medical community including the national board of the Medical Marketing Association of America, the community board of directors for the Northridge Hospital Medical Center and the Los Angeles chapter of the Juvenile Diabetes Research Foundation. She has been professionally active in the diabetes community for many years, having served in various appointed and elected positions with the American Diabetes Association (ADA), the Juvenile Diabetes Research Foundation International (JDRF), and the American Association of Diabetes Educators (AADE).

Vice President of Intellectual Property
Laura Johnson

Laura Johnson was promoted to Vice President of Intellectual Property in September 2008. In her previous role as DexCom's Director of Intellectual Property, Ms. Johnson has been instrumental in developing and aligning DexCom’s patent strategy to achieve business goals across a range of development groups and activities. Prior to joining DexCom, Ms. Johnson served as a patent agent at a local law firm, and prior thereto, served in a technical role at Peregrine Systems, Inc. From 1993 to 1999, Ms. Johnson served as a Patent Examiner at the U.S. Patent and Trademark Office in Virginia, examining patents in the technology area of implantable devices. Ms. Johnson holds a BS in Mechanical Engineering from Grove City College in Grove City, PA.

Vice President of Legal Affairs
John Lister

John Lister was promoted to Vice President of Legal Affairs in May 2009. In this capacity, Mr. Lister oversees DexCom's legal and human resources matters. From January 2008 to May 2009, Mr. Lister served as DexCom’s Director of Legal Affairs. Prior to joining DexCom, Mr. Lister served as a corporate attorney with Fenwick & West where he specialized in corporate finance, mergers and acquisitions, corporate compliance and general business matters for life sciences and technology companies. Mr. Lister received a BA from Claremont McKenna College, and a JD from the University of San Francisco. Mr. Lister is a member of the State Bar of California.

Vice President of Operations
Jeffrey C. Moy

Jeffrey C. Moy was promoted to Vice President of Operations in September 2008. In this capacity, Mr. Moy will be responsible for overseeing DexCom's manufacturing, supply chain, and facility departments. Mr. Moy previously served as DexCom’s Senior Director of Operations since September of 2007. From October 1998 to August 2007, Mr. Moy served as Senior Director and Director of Manufacturing of Biosite, an immunodiagnostics company where he facilitated the scale-up of their manufacturing operations. From 1982 to 1998, Mr. Moy served in various manufacturing roles at Chiron Diagnostics including Process Engineer and Operations Manager.

Mr. Moy received his Bachelor of Science degree in Bioengineering from the University of Pennsylvania and his Master of Engineering degree in Biochemical Engineering from Cornell University.

Chief Operating Officer
Steven R. Pacelli

Steven Pacelli was promoted to Chief Operating Officer in June 2010. In this role, Mr. Pacelli is responsible for the strategic and operational leadership of DexCom's sales, marketing and other core commercial functions, including finance, customer support, quality, corporate development, managed care, human resources, legal and intellectual property and investor relations. Mr. Pacelli has served in various roles with DexCom since April 2006, including as its Chief Administrative Officer, its Senior Vice President of Corporate Affairs, and its Vice President of Legal Affairs. From March 2003 to April 2006, Mr. Pacelli served as a corporate attorney with Stradling Yocca Carlson & Rauth where he specialized in public and private finance, mergers and acquisitions, and general corporate matters for life sciences and technology companies. From February 2001 to March 2003, Mr. Pacelli served as Vice President of Corporate Development, Secretary, and General Counsel of Axcelerant, Inc., a provider of secure managed business network services. From January 2000 to January 2001, Mr. Pacelli served as Vice President, Secretary, and General Counsel of Flashcom, Inc., a provider of consumer broadband DSL services. Mr. Pacelli received a BA from the University of California, Los Angeles, and a JD from the University of Virginia. Mr. Pacelli is a member of the State Bar of California.

Vice President and Chief Financial Officer
Jess Roper

Jess Roper was promoted to Vice President and Chief Financial Officer in March 2008. Mr. Roper joined DexCom in March 2005 as its Director of Finance, and served as its Interim Chief Financial Officer from July 2007 through March 2008. He has over 15 years of financial management and auditing experience. Mr. Roper previously held financial management positions with two other NASDAQ listed companies and one venture funded company, and has been a key participant in two initial public offerings, acquisitions/divestitures, and several equity and debt financings.

Mr. Roper was also an auditor with PricewaterhouseCoopers, and a bank and information systems examiner with the Office of the Comptroller of the Currency. Mr. Roper holds a BS in Finance, an MS in Corporate Accountancy, and is a certified public accountant in the state of California.

Chief Technical Officer
Jorge A. Valdes

Jorge Valdes was promoted to Chief Technical Officer in June 2010. In this role, Mr. Valdes is responsible for the strategic and operational leadership of DexCom's research and development functions, including clinical and regulatory, as well as information technology and manufacturing operations. Mr. Valdes previously served the company since November 2005 as its Senior Vice President of Operations and as its Vice President of Engineering. From July 1999 to March 2005, Mr. Valdes served as Vice President of Engineering at Advanced Fibre Communications, or AFC, a provider of broadband access solutions. Mr. Valdes also served as General Manager for the fiber to the premise (FTTP) business unit of AFC beginning in May 2004. From May 1985 until July 1999, Mr. Valdes held positions at Racal-Datacom, Inc., a manufacturer of data communication products, in engineering management, product development and product management. Mr. Valdes received his BS and an MBA from the University of Miami, Florida.

Terrance H. Gregg

Terrance H. Gregg is President and CEO of DexCom, Inc. He is also currently a Special Venture Partner with Galen-Partners, a private equity firm specializing in the healthcare industry. In 2002 he retired as President of Medtronic MiniMed, a world leader in diabetes management systems. He became President and Chief Operating Officer of MiniMed, Inc. in 1996 and was instrumental in Medtronic's $3.4 billion acquisition of MiniMed in 2001. He also served in executive positions with Smith and Nephew and Allergan, Inc.

Mr. Gregg served as the 2003-2004 Chair of the Research Foundation Board of the American Diabetes Association.

Mr. Gregg received a Bachelor of Science degree from Colorado State University in 1971. In 2003, Mr. Gregg and his wife were recognized by the American Diabetes Association with an award for Outstanding Service in Diabetes Research Funding.

Jonathan Lord

Jonathan Lord, M.D. is Chairman of DexCom’s Board of Directors and has served as a director since 2008. Dr. Lord served as President and Chief Executive Officer of Navigenics, Inc. during 2009 and 2010 and serves on Navigenics’ board of directors. Dr. Lord also serves as a director of Stericyle, Inc. and Veracyte, Inc. Dr. Lord previously served as Chief Innovation Officer for Humana Inc. In that role, Dr. Lord was responsible for designing innovative health plan products and leading processes that enable people to navigate the healthcare system and support their health needs.

Dr. Lord created Humana's Innovation Center, a functional blend of research, (including consumer research, outcomes research, and predictive science), product design, and consumer experience engineering that is unique to the health benefits industry. His belief in a workplace that encourages exploration, discovery, and personal growth has led to industry-leading products, patent-pending innovations in predictive science, and an aggressive entrepreneurship taking the company into global business relationships. Prior to Humana, Dr. Lord worked with Health Dialog, a Boston-based Internet provider of health information to more than 5 million Americans, where he served as president and became a leader in e-enabled healthcare. Prior to joining Health Dialog, he served as chief operating officer of the American Hospital Association in Washington DC, executive vice president of Anne Arundel Medical Center in Annapolis, MD, and executive vice president of Sun Health in Charlotte, NC.

A board-certified forensic pathologist, Dr. Lord began his medical career in the U.S. Navy, where he spent 11 years on active duty, most recently as director of the Naval Medical Command's Quality Assurance Division in the Office of the Surgeon General. He also served as a consultant and surveyor for the Joint Commission on Accreditation of Health Care Organizations. Dr. Lord has published articles on topics ranging from risk management and quality assurance to prostaglandin biosynthesis. In 2002, he received the Karen Coughlin Individual Disease Management Leadership Award from the Disease Management Association of America (DMAA), honoring his contributions to advancements in the care of the millions of U.S. citizens with chronic disease.

His vision, leadership, and talent for change management have led to appointments to several national boards. As president of the Disease Management Association of America (DMAA) from 2001-2002, Dr. Lord led the organization to restructure its operations, significantly increase its membership and revenues and establish branches in Europe, Asia, and Australia. Also in 2002, he began a three-year term on the National Advisory Council for Healthcare Research and Quality. This prestigious appointment placed him among only 21 distinguished healthcare leaders lending advice to the U.S. Secretary of Health and Human Services.

In 2008, Dr. Lord was invited by the Department of Health and Human Services to serve on the Centers for Disease Control and Prevention (CDC) Advisory Committee to the Director. The 21-member committee advises CDC leadership on key strategic issues to assist the agency in fulfilling its vision of health protection and health equity.

Kevin Sayer

Kevin Sayer has served as Chief Financial Officer of Biosensors International Group, Ltd., a medical technology company developing, manufacturing, and commercializing medical devices used in interventional cardiology and critical care procedures. Prior to joining Biosensors International Group, Mr. Sayer served as an independent healthcare and medical technology industry consultant. From 2004 to 2005, Mr. Sayer was Executive Vice President and Chief Financial Officer of Specialty Laboratories, Inc., a company offering clinical reference laboratory services. Mr. Sayer also served as Chief Financial Officer of MiniMed, Inc., a medical technology company focused on insulin pumps for people with diabetes, from May 1994 until its acquisition by Medtronic, Inc. in August 2001. Mr. Sayer is a Certified Public Accountant and received his Master's Degree in Accounting and Information system concurrently with a Bachelor's Degree in Accounting, both from Brigham Young University.

Jay Skyler, MD

Dr. Jay Skyler is a Professor of Medicine, Pediatrics, & Psychology at the University of Miami, Miami, Florida, in the Division of Endocrinology, Diabetes, & Metabolism in the Department of Medicine, of which he was the Director from 2000 to 2004; and Associate Director for Academic Programs in the Diabetes Research Institute. He is Chairman of the NIH (NIDDK)-sponsored Type 1 Diabetes TrialNet, a nationwide network conducting clinical trials to prevent type 1 diabetes or interdict the type 1 diabetes disease process. His research interests are in clinical aspects of diabetes, particularly improving the care of type 1 diabetes through meticulous glycemic control, psychosocial and behavioral support, and immune intervention. He is widely acclaimed for developing "algorithms" for patient adjustment of insulin doses.

Dr. Skyler is a past President of the American Diabetes Association, the International Diabetes Immunotherapy Group, and the Southern Society for Clinical Investigation, and was a Vice President of the International Diabetes Federation. He served as a member of the Endocrinology, Diabetes, and Metabolism Subspecialty Examining Board of the American Board of Internal Medicine, as Chairman of the Council of Subspecialty Societies of the American College of Physicians (ACP) and a member of the ACP Board of Regents. He was founding Editor-in-Chief of Diabetes Care, and currently is Scientific Editor of International Diabetes Monitor and is Associate Editor of Diabetes Technology & Therapeutics.

He has a bachelor of science degree from Pennsylvania State University and a doctor of medicine degree from Jefferson Medical College. He served as an intern, resident, and fellow, and was on the faculty of Duke University.

Vice President of Strategic Affairs
Richard C. Yang

Richard C. Yang was promoted to Vice President of Strategic Affairs in September 2008. Mr. Yang is responsible for the management and output of the global strategic planning function. Mr. Yang previously served as DexCom's Director of Hospital Technologies.

Prior to joining DexCom, Mr. Yang served as the Marketing Director for a start up orthopedics company, Pegasus Biologics. For ten years, Mr. Yang held positions of increasing responsibility with medical device companies including Integra LifeSciences (Orthopedics), Karl Storz Endoscopy (Neurosurgery) and Medtronic Diabetes where he was responsible for product management and business development roles. While at Medtronic Diabetes, Mr. Yang managed their entry and growth in Asia Pacific. Mr. Yang received a Bachelor of Science degree in Biological Sciences at the University of California, Irvine.

Eric J. Topol

Eric J. Topol, M.D. is the Director of the Scripps Translational Science Institute, a National Institutes of Health funded program of the Clinical and Translational Science Award (CTSA) Consortium. In 2009, he was named the Gary and Mary West Endowed Chair of Innovative Medicine. He is Professor of Translational Genomics at The Scripps Research Institute, the Chief Academic Officer of Scripps Health, and a Senior Consultant cardiologist practitioner at Scripps Clinic.

Prior to coming to Scripps, he served on the faculty of Case Western as a professor in genetics, chaired the Department of Cardiovascular Medicine at Cleveland Clinic for 15 years and raised its status to rank #1 by US News and World Report for 11 consecutive years, and founded the Cleveland Clinic Lerner College of Medicine. His work in the genomics of heart attack has led to discovery of key genes (MEF2A deletion, THSB-4 variant) which led to recognition by the American Heart Association top 10 research advances in 2002 and 2004. As a leader in clinical trials of novel therapeutics, he administered recombinant t-PA to the first patient in 1984, pioneered and led the clinical development of clopidogrel (Plavix), bivalirudin (Angiomax), and abciximab (ReoPro). He has over 1,000 original peer reviewed publications, and has edited over 30 books, including the Textbook of Interventional Cardiology (5th ed), and the Textbook of Cardiovascular Medicine (3rd ed). Dr. Topol has been elected to the Institute of Medicine of the National Academy of Sciences, the American Association of Physicians and recognized by the Institute of Scientific Information (ISI) to be in the top 10 cited biomedical researchers in medicine in the past decade.

Dr. Topol has been a medical innovator in wireless medicine. He served on the Scientific Advisory Board of Cardionet, which offers continuous ECG monitoring via the web and was the first public company in wireless health, and currently is on the Board of Directors of Triage Wireless, a manufacturer of complete vital sign monitoring wireless technology. He is the Chief Medical Officer and Founding Board Member of the newly established Gary and Mary West Wireless Health Institute

Nick Augustinos

Nicholas Augustinos is healthcare senior director for the Cisco Internet Business Solutions Group (IBSG). He brings 24 years of broad managerial and consulting experience and expertise working in business-to-business and business-to-consumers applications and services. He has worked with a diverse range of leading healthcare organizations including healthcare delivery systems, healthcare insurers and government/public organizations. Nick is leading Global Healthcare Solutions for IBSG working with network architects, engineers and business development managers, providing direction and thought leadership on connected healthcare.

Prior to Cisco, he was Partner and Senior Strategic Consulting Expert, Global Health Services, for CSC. Prior to joining CSC, he was Vice President, Care Data Exchange for CareScience, leading product development and services in the clinical document sharing space. Nick was also Vice President for Healtheon/WebMD, responsible for marketing and sales for the company’s products and services. Prior to that, he was with Deloitte Consulting and was instrumental in establishing the healthcare practice for Deloitte’s San Francisco office, managing numerous projects for payers, providers, and integrated delivery networks. He started his career in healthcare as Vice President, Administration, of CliniShare. Nick holds a seat at the Board of Directors of Continua Alliance – a non-profit, open industry coalition of the healthcare and technology companies collaborating to improve the quality of personal healthcare.